Change Agents Corporation: appoints director Eric Weisblum

What happened

• On Oct 14, 2026 the filing says the Company appointed Eric Weisblum as an independent director on the Company’s board of directors, effective Oct 12, 2026.
• The filing says Mr. Weisblum will serve on each of the Audit, Compensation and Nominating and Corporate Governance Committees.

Key details

• Mr. Weisblum has been chief executive officer of Silo Pharma Inc since 2020 and founded that biopharmaceutical company.
• The filing says he has nearly 20 years of experience in structuring and trading financial instruments and was a registered representative with Domestic Securities holding Series 7, Series 63 and Series 55 registrations.
• From 1993 to 2002 he originated, structured, traded and placed structured financing transactions at M.H. Meyerson & Co. Inc.
• The filing says there is no arrangement or understanding with any person other than the Company’s directors regarding his selection, he is not related to any director or executive officer, and the Company is not aware of any transaction requiring Item 404(a) disclosure.

Why it may matter

• The filing reports Item 5.02 (Departure of Directors or Certain Officers; Election of Directors), which covers changes in directors or certain officers and related disclosures.
• The filing does not show why the insider traded or why the company acted.